Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Severe COVID-19
NCT04661527Phase 2Unknown
- Sponsor
- Universidad de Navarra
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sarilumab in coronavirus disease 2019 (COVID-19), sponsored by Universidad de Navarra. Primary endpoint: Change in a severity rating on a 7-point ordinal scale at 15 days. Status: unknown.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04661527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661527.